Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Evolution of myeloid-mediated immunotherapy resistance in prostate cancer

Nature(2024)10.1038/s41586-024-08290-3Source: DataRank Database

Evolution of myeloid-mediated immunotherapy resistance in prostate cancer is a research paper published in Nature (2024). On theSindex it has a DataRank of 2.2. It has been cited 154 times, with 100 citing works in its 1-hop citation network.

N/A

2.2DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access154 citations · 100 citing works in its network

Download PDF

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

GEOGSE274229

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 28.79)OA: hybridTopics (85)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 35%Citation Network 65%

Base Score Contribution

0.757

From this paper's citation signal

Citation Network Contribution

1.4

From 80 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

Mitochondrial control of macrophage polarity in tumors
Immunity20254 citations10 referencesContributes 0.161
A2A receptors: a new target for immunotherapy resistance in prostate cancer
Purinergic Signalling20251 citations8 referencesContributes 0.087
Targeting SPP1+ macrophages via the SPP1-CD44 axis reveals a key mechanism of immune suppression and tumor progression in ovarian cancer
International Immunopharmacology202535 citations42 referencesContributes 0.085
SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Cancer Immunology Research202518 citations47 referencesContributes 0.063
Single-cell transcriptomic analyses provide insights into SPP1+ TAM-mediated immune suppression and CD8+ T cell dysfunction in lung cancer
Cancer Immunology Immunotherapy202510 citations45 referencesContributes 0.053

Authors (17)

Zenghua Fan ORCID,Matthew Clark ORCID,Averey Lea,Diamond Luong ORCID,Ali Setayesh

Live enrichment

PubMed:39633050 OpenAlex:https://openalex.org/W4405029585

National Institutes of Health

Grant: 5P30DK063720-03

ISLET PRODUCTION FACILITY CORE

National Institutes of Health

Grant: 1S10OD021822-01

BD FACSAria Fusion Cell Sorter

National Institutes of Health

Grant: 5R35CA253175-03

Determinants of response to cancer immunotherapy

National Institutes of Health

Grant: 1U01CA233100-01

Molecular and immune drivers of immunotherapy responsiveness in prostate cancer

NIDDK NIH HHS

Grant: P30 DK063720

NCI NIH HHS

Grant: R35 CA253175

NIH HHS

Grant: S10 OD021822

NCI NIH HHS

Grant: U01 CA233100

FWCI

28.79

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1038/s41586-024-08290-3

publisherhttps://doi.org/10.1038/s41586-024-08290-3

publisherhttps://www.nature.com/articles/s41586-024-08290-3.pdf

publisherhttps://www.nature.com/articles/s41586-024-08290-3

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39633050

Fields of Study

Cancer Immunotherapy and BiomarkersAdenosine and Purinergic SignalingImmunotherapy and Immune Responses0301 basic medicine03 medical and health sciences0303 health sciencesMaleAnimalsHumansMiceProstatic Neoplasms, Castration-ResistantDrug Resistance, NeoplasmImmunotherapyCD8-Positive T-LymphocytesOsteopontinImmune Checkpoint InhibitorsTumor-Associated MacrophagesSingle-Cell AnalysisReceptors, Granulocyte-Macrophage Colony-Stimulating FactorDisease ProgressionB7-H1 AntigenSignal TransductionMyeloid CellsDisease Models, Animal

MeSH Terms

Immune Checkpoint InhibitorsTumor-Associated MacrophagesAdenosineAnimalsDisease Models, AnimalHumansImmunotherapyMaleSignal TransductionReceptors, Granulocyte-Macrophage Colony-Stimulating FactorCD8-Positive T-LymphocytesDisease ProgressionDrug Resistance, NeoplasmMyeloid CellsMiceOsteopontinAdenosine A2 Receptor AntagonistsSingle-Cell AnalysisB7-H1 AntigenProstatic Neoplasms, Castration-Resistant

Keywords

Prostate cancerCancer researchImmunotherapyPopulationImmune systemImmune checkpointImmunosuppressionCancer immunotherapyBiologyImmunologyMedicineCancerInternal medicineMaleAdenosineDrug ResistanceCD8-Positive T-LymphocytesCastration-ResistantArticleB7-H1 AntigenMiceReceptorsTumor-Associated MacrophagesAnimalsHumansMyeloid CellsImmune Checkpoint InhibitorsAnimalProstatic NeoplasmsGranulocyte-Macrophage Colony-Stimulating FactorAdenosine A2 Receptor AntagonistsProstatic Neoplasms, Castration-ResistantDisease Models, AnimalDrug Resistance, NeoplasmReceptors, Granulocyte-Macrophage Colony-Stimulating FactorDisease ModelsDisease ProgressionNeoplasmOsteopontinSingle-Cell AnalysisSignal Transduction

Sustainable Development Goals

SDG 0: Good health and well-being